Bioxhale’s team and Renfrew Group International have been working together on the development of device and kit of parts to deliver Intrinsically Valid Sampling, a system which is simple and economic to operate and which aims to be the standard tool for breath sampling used in research or commercial applications in labs worldwide.
The inventors of the BreathTrace device, Dr Dahlia Salman, Prof Paul Thomas and Prof Chris Brightling were also part of the EMBER (East Midlands Breathomics Pathology Node) consortium. EMBER aimed to deliver near-patient and remote sensing technologies to analyse breath and will create opportunities to develop new methods to analyse complex “omics” data. It’s hoped these could give an instant diagnosis and help doctors pick the best treatments for a range of conditions, including cancers, respiratory infections and diseases such as asthma and chronic obstructive pulmonary disease.